10 completed, 2 active not recruiting, 1 terminated. 7 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 2 |
| Phase 1 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow Filgrastim (G-CSF): new trials by email Literature Review of Filgrastim (G-CSF) trials Research Report on Filgrastim (G-CSF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| G-CSF-Related Bone Pain and Supportive Care Strategies in Patients With Solid Tumors Filgrastim (G-CSF), Naproxen, Loratadine - Solid Tumors, Chemotherapy-induced Neutropenia | Completed | Ankara Etlik City Hospital | 190 | 2025-09-27 | 2026-10-09 | |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| Epigenetic Reprogramming in Relapse/Refractory AML Decitabine, Vorinostat, Filgrastim (G-CSF) - Acute Myelogenous Leukemia | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 37 | 2017-07-11 | 2025-10-16 |
| TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03) Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF) - Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment | Phase 1 | Completed | University of Illinois at Chicago | 12 | 2014-01-14 | 2024-11-13 |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma Total Marrow Irradiation, Autologous Transplant, Melphalan - Multiple Myeloma | Phase 1 | Terminated | University of Illinois at Chicago | 3 | 2014-01-10 | 2019-10-14 |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Miltenyi reagent system, Fludarabine, Cyclosporine - Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 116 | 2006-09-01 | 2021-06-16 |
| Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease Gemcitabine, Fludarabine, Melphalan - Hodgkin's Disease | Phase 2 | Completed | M.D. Anderson Cancer Center | 52 | 2005-07-01 | 2018-05-09 |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Etoposide, Interferon-alpha, Rituximab - Lymphoproliferative Disorder, HHV-8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 75 | 2004-10-28 | 2026-10-23 |
| R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma Rituximab, Cyclophosphamide, Cytarabine - Lymphoma | Phase 2 | Completed | University of Miami | 22 | 2004-04-01 | 2015-11-10 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 13 | 1995-12-01 | 2012-07-31 |
| Combination Chemotherapy in Treating Patients With Lymphoma Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa - Lymphoma | Phase 3 | Completed | M.D. Anderson Cancer Center | 116 | 1995-10-30 | 2018-11-15 |
| Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer Filgrastim (G-CSF), Carmustine, Cisplatin - Breast Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 184 | 1995-09-26 | 2018-11-06 |
| High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride - Breast Cancer | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 1995-09-01 | 2012-07-31 |
Leukemia (3) · Breast Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Multiple Myeloma (2) · Recurrence (2) · Anemia, Sickle Cell (1) · Depression (1) · Disease Progression (1) · Fatigue (1) · HIV Infections (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphadenopathy (1)
M.D. Anderson Cancer Center (5) · National Heart, Lung, and Blood Institute (NHLBI) (2) · University of Illinois at Chicago (2) · Ankara Etlik City Hospital (1) · National Cancer Institute (NCI) (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · University of Miami (1)
United States (12) · Australia (1) · Canada (1) · Turkey (Türkiye) (1)
Damiano Rondelli, MD (1) · Issa Khouri, MD (1) · Izidore S. Lossos, MD (1) · James Gajewski, MD (1) · John F Tisdale, M.D. (1) · Michele L. Donato, MD (1) · Minocher M Battiwalla, M.D. (1) · Paolo Anderlini, MD (1) · Pritesh Patel, MD (1) · Richard E. Champlin, MD (1) · Robert Yarchoan, M.D. (1)
PMID 20038221, PMID 21487108, PMID 22133778, PMID 23065508, PMID 23524640, PMID 24174627, PMID 25331113, PMID 29065747, PMID 29674506, PMID 33720337, PMID 33735476, PMID 38941593, PMID 41845569
P30CA016672 (4)